ExodusPoint Capital Management LP Acquires New Shares in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS)

ExodusPoint Capital Management LP bought a new stake in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) during the 4th quarter, Holdings Channel.com reports. The institutional investor bought 13,516 shares of the company’s stock, valued at approximately $72,000.

Several other hedge funds and other institutional investors have also made changes to their positions in CRVS. EntryPoint Capital LLC purchased a new position in Corvus Pharmaceuticals during the 4th quarter valued at about $624,000. Raymond James Financial Inc. acquired a new position in shares of Corvus Pharmaceuticals during the 4th quarter worth approximately $583,000. Geode Capital Management LLC lifted its stake in Corvus Pharmaceuticals by 22.4% in the 3rd quarter. Geode Capital Management LLC now owns 563,009 shares of the company’s stock valued at $2,974,000 after buying an additional 102,869 shares in the last quarter. State Street Corp grew its holdings in Corvus Pharmaceuticals by 48.2% during the 3rd quarter. State Street Corp now owns 178,246 shares of the company’s stock valued at $941,000 after buying an additional 57,943 shares during the last quarter. Finally, Jane Street Group LLC acquired a new position in shares of Corvus Pharmaceuticals in the third quarter worth $265,000. Institutional investors and hedge funds own 46.64% of the company’s stock.

Wall Street Analyst Weigh In

CRVS has been the subject of a number of recent research reports. Oppenheimer reiterated an “outperform” rating and set a $15.00 price objective (up previously from $14.00) on shares of Corvus Pharmaceuticals in a research report on Wednesday, March 26th. HC Wainwright reissued a “buy” rating and set a $11.00 price objective on shares of Corvus Pharmaceuticals in a research note on Wednesday, March 26th. One analyst has rated the stock with a sell rating, three have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $15.67.

Corvus Pharmaceuticals Price Performance

CRVS opened at $3.03 on Tuesday. Corvus Pharmaceuticals, Inc. has a 12 month low of $1.30 and a 12 month high of $10.00. The business has a 50-day moving average of $4.02 and a two-hundred day moving average of $5.85. The stock has a market capitalization of $206.45 million, a price-to-earnings ratio of -3.26 and a beta of 0.71.

Corvus Pharmaceuticals (NASDAQ:CRVS) last issued its quarterly earnings results on Tuesday, March 25th. The company reported ($0.18) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.06). Equities research analysts anticipate that Corvus Pharmaceuticals, Inc. will post -0.63 earnings per share for the current year.

Corvus Pharmaceuticals Profile

Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis.